background
analyz
nationwid
registri
pediatr
patient
hemophagocyt
lymphohistiocytosi
hlh
korea
assess
clinic
genet
featur
treatment
outcom
pediatr
hlh
method
korea
histiocytosi
work
parti
retrospect
analyz
data
pediatr
patient
diagnos
hlh
result
studi
cohort
case
categor
famili
hlh
presum
secondari
hlh
unspecifi
hlh
evalu
patient
concomit
epsteinbarr
viru
infect
evalu
patient
central
nervou
system
cn
involv
frequent
famili
group
evid
case
genet
test
reveal
predomin
mutat
high
incid
two
recurr
splice
mutat
c
overal
surviv
rate
famili
group
presum
secondari
group
overal
surviv
rate
among
patient
underw
allogen
hematopoiet
stem
cell
transplant
multivari
analysi
younger
age
diagnosi
sever
transaminasemia
coagul
abnorm
independ
prognost
factor
surviv
respons
initi
treatment
also
signific
indic
outcom
conclus
studi
show
uniqu
predomin
mutat
vulner
epsteinbarr
viru
infect
korean
children
hlh
emphas
prognost
signific
age
liver
dysfunct
treatment
respons
diseas
multicent
prospect
trial
build
present
result
warrant
identifi
subgroup
patient
poor
prognosi
identifi
optim
treatment
hemophagocyt
lymphohistiocytosi
hlh
potenti
fatal
diseas
caus
dysregul
immun
respons
overwhelm
inflamm
hlh
categor
two
distinct
form
primari
famili
hlh
fhl
secondari
hlh
flh
subcategor
five
subtyp
accord
caus
gene
mutat
link
respect
secondari
hlh
trigger
infect
malign
rheumat
diseas
without
known
genet
predisposit
interestingli
ethnic
differ
genet
suscept
fhl
vulner
epsteinbarr
virusassoci
hlh
report
establish
diagnost
criteria
use
immunochemotherapi
without
appropri
allogen
hematopoiet
stem
cell
transplant
hsct
significantli
improv
surviv
outcom
patient
hlh
earli
recognit
prompt
initi
treatment
mandatori
improv
prognosi
howev
reliabl
outcom
predictor
hlh
riskdefin
treatment
strategi
remain
adequ
establish
although
understand
hlh
increas
significantli
largescal
nationwid
studi
heterogen
diseas
still
lack
present
studi
conduct
analyz
korean
nation
registri
pediatr
hlh
therebi
investig
epidemiolog
featur
ethnic
characterist
korean
pediatr
patient
hlh
well
gener
clinic
featur
prognost
factor
hlh
korea
histiocytosi
work
parti
retrospect
collect
data
children
adolesc
hlh
member
hospit
total
patient
diagnos
hlh
regist
korean
institut
case
report
form
includ
inform
demograph
characterist
clinic
laboratori
radiolog
find
present
genet
mutat
analysi
type
treatment
respons
treatment
allogen
hematopoiet
stem
cell
transplant
surviv
outcom
patient
malignancyassoci
hlh
regist
studi
classif
hlh
diagnos
base
diagnost
criteria
propos
histiocyt
societi
updat
sinc
korea
histiocytosi
work
parti
recommend
patient
present
suspici
clinic
laboratori
featur
hlh
undergo
genet
test
disord
central
laboratori
irrespect
age
present
studi
patient
found
genet
abnorm
earlyonset
diseas
yr
famili
histori
without
genet
evalu
design
famili
hlh
patient
whose
genet
test
reveal
genet
abnorm
famili
histori
hlh
design
presum
secondari
hlh
patient
could
defin
famili
secondari
hlh
due
unavail
genet
test
data
design
unspecifi
hlh
cn
involv
defin
either
presenc
neurolog
symptom
pleocytosi
andor
proteinosi
cerebrospin
fluid
csf
demonstr
abnorm
magnet
reson
imag
mri
high
signal
intens
lesion
hemorrhag
atrophi
leptomening
enhanc
ttest
use
compar
differ
parametr
variabl
chisquar
test
fisher
exact
test
use
assess
differ
group
kaplanmei
method
use
estim
surviv
probabl
logrank
test
use
test
prognost
signific
variou
risk
factor
multivari
cox
analysi
perform
assess
associ
clinic
variabl
prognosi
p
consid
statist
signific
statist
analys
perform
use
spss
version
statist
packag
social
scienc
ibm
armonk
ny
usa
demograph
data
clinic
featur
patient
hlh
initi
present
shown
tabl
twentyf
patient
categor
famili
hlh
base
famili
histori
andor
genet
mutat
presum
secondari
hlh
unspecifi
hlh
patient
clinic
symptom
sign
suggest
ch
ediakhigashi
syndrom
griscelli
syndrom
hermanskypudlak
syndrom
report
total
hlh
cohort
patient
male
femal
male
femal
ratio
median
age
diagnosi
yr
rang
yr
patient
younger
month
proport
infant
younger
month
significantli
higher
famili
hlh
group
presum
secondari
hlh
group
p
median
age
diagnosi
famili
group
significantli
younger
presum
secondari
hlh
group
yr
vs
yr
p
proport
patient
famili
hlh
tend
decreas
age
patient
increas
patient
yr
age
genet
mutat
consist
fhl
notabl
infant
patient
shown
genet
background
associ
hlh
particular
young
infant
younger
month
age
highli
like
genet
predisposit
hlh
fig
initi
present
nearli
patient
subject
fever
hepatosplenomegali
splenomegali
preval
famili
hlh
group
presum
secondari
hlh
group
p
evalu
patient
neurolog
symptom
proport
patient
neurolog
symptom
differ
famili
presum
secondari
hlh
group
characterist
laboratori
histopatholog
find
shown
tabl
patient
bicytopenia
predomin
anemia
thrombocytopenia
significantli
higher
incid
anemia
p
thrombocytopenia
p
bicytopenia
p
famili
hlh
group
presum
secondari
hlh
group
elev
lactat
dehydrogenas
ldh
level
iul
common
p
transaminasemia
margin
common
p
presum
secondari
hlh
group
differ
laboratori
find
statist
signific
two
group
notabl
mani
patient
liver
dysfunct
elev
level
aspart
transaminas
ast
andor
alanin
transaminas
alt
iul
hyperbilirubinemia
mgdl
hypoalbuminemia
gdl
quarter
patient
signific
coagul
abnorm
aptt
also
patient
elev
level
serum
ldh
cn
involv
hlh
cohort
summar
tabl
evalu
patient
cn
involv
csf
mri
abnorm
observ
evalu
patient
patient
famili
hlh
frequent
cn
involv
frequent
mri
abnorm
p
csf
proteinosi
p
presum
secondari
hlh
wherea
proport
patient
clinic
neurolog
symptom
differ
two
group
rate
concomit
ebv
infect
significantli
lower
patient
cn
involv
without
vs
p
evalu
patient
ebv
concomit
ebv
infect
ebv
infect
tend
common
presum
secondari
hlh
group
famili
hlh
group
without
statist
signific
vs
p
significantli
associ
concomit
hyperbilirubinemia
vs
p
genet
test
carri
patient
test
patient
show
genet
mutat
common
genet
mutat
mutat
mutat
patient
mutat
among
patient
mutat
biallel
mutat
monoallel
mutat
mutat
splice
mutat
frameshift
mutat
nonsens
mutat
notabl
recurr
splice
c
c
predomin
either
mutat
found
patient
mutat
detail
data
mutat
separ
report
two
patient
whose
detail
data
mutat
avail
frameshift
mutat
biallel
monoallel
mutat
major
studi
patient
evalu
patient
treat
immunochemotherapi
wherea
case
treat
treatment
methylprednisolon
intraven
immunoglobulin
antithymocyt
globulin
patient
treatment
due
spontan
resolut
rapid
progress
diseas
tabl
data
analysi
treatment
respons
avail
among
patient
hlh
receiv
treatment
eighti
patient
achiev
complet
resolut
show
improv
contrast
patient
reactiv
persist
diseas
minim
improv
wk
initi
treatment
patient
die
refractori
diseas
tabl
total
cohort
enrol
hlh
patient
die
within
wk
diagnosi
beyond
wk
lead
overal
surviv
os
rate
fig
os
rate
significantli
poorer
famili
hlh
group
presum
secondari
hlh
group
unspecifi
hlh
group
vs
vs
p
fig
result
univari
analysi
put
prognost
factor
os
accord
type
diseas
shown
figur
distribut
famili
presum
secondari
hlh
age
classifi
patient
tabl
overal
younger
age
cn
involv
sever
transaminasemia
ast
alt
iul
sever
cholestasi
total
bilirubin
mgdl
coagul
abnorm
signific
indic
poor
prognosi
famili
hlh
group
coagul
abnorm
margin
signific
prognost
factor
cn
involv
age
found
significantli
associ
surviv
outcom
presum
secondari
hlh
group
younger
age
sever
transaminasemia
coagul
abnorm
cn
involv
found
predictor
poor
surviv
outcom
overal
diseas
statu
treatment
respons
repres
ferritin
level
wk
treatment
found
signific
indic
outcom
diseas
statu
wk
indic
poor
outcom
famili
presum
secondari
hlh
group
wherea
ferritin
level
wk
signific
indic
famili
group
presum
secondari
group
overal
multivari
cox
regress
analysi
reveal
younger
age
diagnosi
hazard
ratio
hr
p
confid
interv
ci
sever
transaminasemia
hr
p
ci
coagul
abnorm
hr
p
ci
independ
prognost
factor
surviv
thirtytwo
patient
hlh
studi
cohort
underw
allogen
hematopoiet
stem
cell
transplant
hsct
reason
use
hsct
famili
hlh
case
activ
diseas
initi
treatment
reactiv
diseas
wherea
nine
patient
receiv
transplant
match
relat
donor
patient
receiv
transplant
unrel
donor
graft
sourc
includ
bone
marrow
patient
granulocyt
colonystimul
factormobil
peripher
blood
cord
blood
busulfan
n
totalbodi
irradiationbas
n
myeloabl
condit
mac
regimen
use
fludarabinebas
reducedintens
condit
ric
regimen
twentyfour
patient
nonact
diseas
time
hsct
activ
diseas
three
patient
develop
graft
failur
three
patient
develop
graft
failur
receiv
cord
blood
graft
mac
ric
patient
receiv
donor
lymphocyt
infus
stem
cell
boost
os
rate
allogen
hsct
type
donor
condit
regimen
statu
prior
hsct
influenc
outcom
cord
blood
graft
tend
associ
poorer
outcom
without
statist
signific
p
fig
seven
patient
die
transplantrel
caus
graft
failur
three
infect
two
heart
failur
one
hemorrhag
one
graftversushost
diseas
one
two
patient
die
refractori
reactiv
diseas
current
studi
repres
first
nationwid
assess
hlh
korea
describ
epidemiolog
clinic
characterist
korean
patient
disord
figur
overal
surviv
rate
patient
hlh
overal
group
accord
type
diseas
b
result
emphas
prognost
signific
cn
involv
liver
dysfunct
includ
sever
cholestasi
sever
transaminasemia
coagul
abnorm
predict
role
treatment
respons
repres
declin
ferritin
level
moreov
present
find
confirm
predomin
mutat
korean
patient
fhl
high
incid
ebvassoci
hlh
korea
fhl
usual
diagnos
infanc
earli
childhood
current
analys
reveal
median
age
diagnosi
fhl
yr
patient
younger
yr
old
highli
like
genet
caus
associ
hlh
thu
genet
evalu
mandatori
patient
present
hlh
infanc
earli
childhood
howev
studi
find
also
show
older
children
might
genet
mutat
consist
fhl
inde
patient
hlh
cohort
older
yr
age
shown
genet
background
previou
studi
report
adolesc
even
older
adult
may
genet
predisposit
hlh
thu
case
suspici
symptom
regardless
age
evalu
famili
hlh
even
trigger
factor
found
clinic
laboratori
featur
present
cohort
compar
previou
report
notabl
patient
found
hemophagocytosi
higher
previou
studi
like
due
limit
avail
nkcell
activ
test
measur
element
diagnost
criteria
hlh
patient
found
hemophagocytosi
thu
meet
diagnost
criteria
hlh
without
two
test
like
includ
present
studi
therefor
high
percentag
hemophagocytosi
studi
emphas
presenc
hemophagocytosi
necessari
requisit
diagnosi
hlh
cn
involv
report
critic
factor
predict
outcom
patient
hlh
current
data
indic
cn
involv
common
famili
group
thu
suggest
genet
suscept
play
import
role
infiltr
activ
lymphocyt
macrophag
cn
cn
involv
found
signific
prognost
factor
presum
secondari
hlh
group
associ
poor
outcom
famili
group
thu
prognost
signific
cn
involv
accord
type
hlh
evalu
larger
studi
present
studi
cohort
patient
hlh
ebv
infect
find
exampl
high
incid
secondari
hlh
associ
ebv
infect
asian
popul
uniqu
vulner
ebv
infect
asian
patient
hlh
suggest
differ
genet
background
contribut
develop
diseas
even
case
secondari
hlh
addit
hlh
patient
document
ebv
infect
lower
rate
cn
involv
higher
rate
cholestasi
suggest
tropism
organ
involv
ebvassoci
hlh
futur
studi
includ
genet
test
itk
implic
ebvassoci
lymphoprolif
disord
differenti
hlh
disord
present
hemophagocyt
syndrom
present
studi
find
confirm
gene
commonli
mutat
korean
patient
fhl
also
suggest
previou
pilot
studi
ethnic
differ
report
relat
genet
predisposit
subtyp
fhl
interestingli
commonli
mutat
gene
fhl
neighbor
countri
korea
japan
china
two
recurr
splice
cwere
found
nearli
threequart
patient
current
studi
cohort
suggest
presenc
founder
effect
mutat
develop
hlh
korea
contrast
c
common
mutat
japanes
patient
common
mutat
european
patient
found
seri
suggest
geograph
ethnic
specif
mutat
caus
fhl
subtyp
current
analys
show
os
rate
compar
previou
studi
patient
famili
hlh
seri
show
significantli
poorer
outcom
death
occur
within
first
month
diseas
presum
secondari
hlh
group
wherea
mani
patient
fhl
succumb
refractori
reactiv
diseas
earli
period
diseas
hsct
abl
rescu
substanti
portion
patient
fhl
refractori
diseas
notabl
use
cord
blood
graft
associ
poor
outcom
thu
optim
condit
regimen
accord
graft
sourc
evalu
futur
studi
present
studi
incorpor
inevit
limit
longterm
retrospect
design
miss
data
inconsist
evalu
use
heterogen
treatment
limit
retrospect
studi
includ
incomplet
test
mutat
absenc
test
mutat
itk
adopt
term
presum
secondari
hlh
patient
without
mutat
leav
possibl
presenc
cryptic
genet
mutat
patient
design
presum
secondari
hlh
thu
requir
cautiou
interpret
result
anoth
limit
present
studi
larger
portion
patient
enrol
earli
period
studi
test
genet
mutat
thu
design
unspecifi
hlh
reliabl
clinic
criteria
distinguish
famili
secondari
hlh
therefor
could
defin
patient
hlh
without
genet
evalu
famili
histori
even
though
report
possibl
trigger
caus
albeit
limit
observ
discret
clinic
featur
famili
presum
secondari
group
prognost
factor
evalu
overal
cohort
could
provid
clinic
implic
futur
research
agenda
conclus
current
analys
reveal
uniqu
genet
suscept
vulner
ebv
infect
korean
children
hlh
age
liver
dysfunct
treatment
respons
found
signific
indic
poor
prognosi
serial
monitor
chang
ferritin
level
initi
treatment
hlh
may
enabl
diseas
statu
follow
allow
predict
treatment
outcom
thu
help
identifi
subgroup
patient
need
intens
treatment
multicent
prospect
trial
warrant
identifi
subgroup
patient
hlh
poor
prognos
find
optim
treatment
case
addit
optim
intens
durat
treatment
patient
presum
secondari
hlh
need
investig
